Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
unclassified
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05328908CT.gov A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04683965CT.gov Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | — | Unknown | — | — | — |
NCT02848079CT.gov TAS-OX for Refractory Metastatic Colon Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tas-102 (this asset) | Bristol-Myers Squibb | P3 | B · 59 |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Barii Sulfas | London North West Healthcare NHS Trust | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Tas-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P3 | BB · 65 |
| Hepatocellular Carcinoma | — | P3 | B · 60 |
| Rectal Carcinoma | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tas-102 in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tas-102-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →